VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization
CAMPBELL, Calif. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on its Second Amended   Joint Prepackaged
View HTML
Toggle Summary VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19 CAMPBELL, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced
View HTML
Toggle Summary VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
- VIVUS to Receive Milestone Payment from Alvogen ; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen , has
View HTML
Toggle Summary VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
CAMPBELL, Calif. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE ®
View HTML
Toggle Summary VIVUS Adopts Stockholder Rights Plan
CAMPBELL, Calif. , Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in
View HTML
Toggle Summary VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents- CAMPBELL, Calif. , Dec.
View HTML
Toggle Summary New Clinical Data Demonstrate VIVUS’ Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
-Data published in International Journal of Eating Disorders show patients in the Qsymia group had 75% decrease in binge day frequency compared with 19% for placebo- CAMPBELL, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today
View HTML
Toggle Summary VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
CAMPBELL, Calif. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos , Chief Executive Officer, will participate in a panel discussion at the Cleveland Clinic 2019 Medical Innovation Summit, which is taking
View HTML
Toggle Summary VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
CAMPBELL, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden , Denmark , Finland , Iceland , Norway , and Poland (the “Concerned Member States”) have accepted the Marketing
View HTML